Skip to main content

Day: January 8, 2024

Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024

Written by Customer Service on . Posted in Public Companies.

Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024Halle (Saale) / Munich, Germany, January 8, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that members of its management team including CEO Frank Weber, MD, CBO Michael Schaeffer, PhD, and CS & IRO Anne Doering, CFA, will host investor meetings, January 8 – 10, 2024, in San Francisco, CA.Vivoryon’s management team will discuss its lead program varoglutamstat, a differentiated investigational small-molecule medicine in development to treat Alzheimer’s disease (AD). The Company remains on track to share VIVIAD Phase 2b final topline data, comprising...

Continue reading

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end Leiden, The Netherlands, January 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today updated full year 2023 guidance, including RUCONEST® and Joenja® revenues, and a progress update on the U.S. launch of Joenja® (leniolisib) for APDS. For the full year 2023, total revenues are expected to increase by 19% to approximately US$245 million (preliminary and unaudited*). Sijmen de Vries, Chief Executive Officer, commented: “We are pleased to have concluded an excellent year in which we transformed Pharming into a multi-product, commercial rare disease biopharmaceutical company. We expect 10% growth in RUCONEST®...

Continue reading

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

Written by Customer Service on . Posted in Public Companies.

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia Ad hoc announcement pursuant to Art. 53ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) shows superior MMR rates at week 48 vs. standard-of-care TKIs (imatinib, nilotinib, dasatinib, and bosutinib) in newly diagnosed Ph+CML-CP patients1Scemblix demonstrated a favorable safety and tolerability profile with fewer adverse events (AEs) and treatment discontinuations vs. standard-of-care TKIs; no new safety signals were observed1With current standard-of-care TKIs, more than 60% of newly diagnosed patients with CML fail to meet molecular response goals...

Continue reading

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Written by Customer Service on . Posted in Public Companies.

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in Geographic Atrophy (GA) to Initiate Mid-2024; First Pivotal Trial Using Vision Preservation as Primary Outcome Measure in GA Clinical Proof-of-Concept Study of ANX1502 First-in-Kind Oral Small Molecule Inhibitor of the Classical Pathway to Initiate in First Half of 2024 Recent Successful $125 Million Financing Extends Operating Runway into Second Quarter 2026 BRISBANE, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today outlined its strategic priorities...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.